Researchers have identified a proteasome-guided haem signalling axis that rewires T-cell metabolism and drives immune exhaustion in cancer patients [1].
This discovery is significant because T-cell exhaustion is a primary barrier to successful cancer treatment. When these immune cells lose their ability to fight tumours, the efficacy of immunotherapies decreases, allowing cancer to persist or grow despite medical intervention [2].
The mechanism occurs within the tumour micro-environment [3]. According to research detailed in a March 18, 2026, press release [1], metabolic stress triggers a specific signalling pathway involving the proteasome and haem [2]. This process effectively reprograms tumour-infiltrating T cells, shifting their metabolic state into one of exhaustion [3].
Once this signalling axis is activated, the T cells undergo a stable transition that hampers their capacity to attack malignant cells [4]. The study suggests that this metabolic rewiring is not a random failure but a guided response to the cellular stress found within tumours [2]. By understanding the precise pathway, from the proteasome to haem signalling, scientists can better identify why some patients do not respond to current therapies [4].
This biological axis acts as a switch that turns off the aggressive nature of the immune system [3]. Because the exhaustion is driven by a specific metabolic signal, it provides a potential target for future drugs designed to "wake up" exhausted T cells [2]. If the proteasome-guided haem signal can be blocked or reversed, the immune system may regain its ability to eliminate cancer cells more effectively [4].
“A proteasome-guided haem signalling axis rewires T-cell metabolism, driving their exhaustion.”
The identification of this specific metabolic pathway shifts the understanding of T-cell exhaustion from a general state of fatigue to a programmable biological process. By pinpointing the proteasome-haem axis as the driver, researchers can move toward developing precision medicines that prevent this rewiring, potentially increasing the success rates of immunotherapies that currently fail in a significant portion of patients.
